Despite the markedly superior clinical efficacy of ciclesonide relative to the placebo, a “placebo effect” was identified, which likely contributed in part to the clinical improvement observed in the ciclesonide-treated group. Ciclesonide inhalation solution administered by the inhalera was well tol- erated and effective at reducing clinical signs and improving QOL in severely asthmatic horses.
Acknowledgments
Declaration of Ethics The Authors have adhered to the Principles of Vet- erinary Medical Ethics of the AVMA.
MEDICINE: NON-INFECTIOUS DISEASES Conflict of Interest
This publication followed the GPP3 guidelines. Drs. Engel, Albrecht, and von Salis-Soglio are em- ployees of Boehringer Ingelheim Vetmedica GmbH, the marketing authorization holder of Aservo Equihaler with ciclesonide as active ingredient. Dr. Mueller is an employee of Boehringer Ingelheim Pharma GmbH & Co KG. Dr. Pirie has acted as consultant to Boehringer Ingelheim Vetmedica GmbH. Dr. Albrecht is co-inventor on a patent re- garding the use of ciclesonide in horses.
